Analogs of SR-141716A (Rimonabant) alter d-amphetamine-evoked [3H] dopamine overflow from preloaded striatal slices and amphetamine-induced hyperactivity

Life Sciences

Volumn 81, Issue 1, 2007, Pages 63-71

  Miller, Dennis K ^a   Rodvelt, Kelli R ^a   Constales, Consuela ^b   Putnam, William C ^b  

^a UNIVERSITY OF MISSOURI   (United States)

^b MIDWEST RESEARCH INSTITUTE   (United States)

Author keywords

Amphetamine; Cannabinoid receptors; CB1 cannabinoid receptor; Cocaine; Dopamine

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; COCAINE; DEXAMPHETAMINE; DOPAMINE; MRI 8273301; MRI 827359; NIDA 41020; RIMONABANT; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN SLICE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE RELEASE; DRUG DEPENDENCE; DRUG DOSE COMPARISON; HYPERACTIVITY; LOCOMOTION; MALE; NEUROCHEMISTRY; NEUROMODULATION; NONHUMAN; RAT;

ANIMALS; BEHAVIOR, ANIMAL; COCAINE; CORPUS STRIATUM; DEXTROAMPHETAMINE; DOPAMINE; DOPAMINE UPTAKE INHIBITORS; HYPERKINESIS; MALE; PIPERIDINES; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, CANNABINOID, CB1; TIME FACTORS; TRITIUM;

RATTUS;

EID: 34250003241     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2007.04.024     Document Type: Article

References (34)

1. Anggadiredja K., Nakamichi M., Hiranita T., Tanaka H., Shoyama Y., Watanabe S., and Yamamoto T. Endocannabinoid system modulates relapse to methamphetamine seeking: possible mediation by the arachidonic acid cascade. Neuropsychopharmacology 29 8 (2004) 1470-1478
2. Bardo M.T. Neuropharmacological mechanisms of drug reward: beyond dopamine in the nucleus accumbens. Critical Reviews in Neurobiology 12 1-2 (1998) 37-67
3. 1R) antagonists as potential pharmacotherapies for drug abuse disorders. Behavioral Pharmacology 16 5-6 (2005) 275-296
4. Carai M.A.M., Colombo G., and Gessa G.L. Rimonabant: the first therapeutically relevant cannabinoid antagonist. Life Sciences 77 19 (2005) 2239-2350
5. Cheer J.F., Wassum K.M., Heien M.L., Phillips P.E., and Wightman R.M. Cannabinoids enhance subsecond dopamine release in the nucleus accumbens of awake rats. Journal of Neuroscience 24 18 (2004) 4393-4400
6. 1 receptor antagonists for the treatment of nicotine addiction. Pharmacology, Biochemistry and Behavior 81 (2005) 387-395
7. 1 receptors control conditioned drug seeking. Trends in Pharmacological Sciences 26 8 (2005) 420-426
8. De Vries T.J., Shaham Y., Homberg J.R., Crombag H., Schuurman K., Dieben J., Vanderschuren L.J.M.J., and Schoffelmeer A.N.M. A cannabinoid mechanism in relapse to cocaine seeking. Nature Medicine 7 10 (2001) 1151-1154
9. 1) receptor ligands for potential use in molecular imaging. Bioorganic & Medicinal Chemistry 14 11 (2006) 3712-3720
10. 2 receptors: immunohistochemical localization in rat brain. Brain Research 1071 1 (2006) 10-23
11. Herkenham M., Lynn A.B., Little M.D., Johnson M.R., Melvin L.S., de Costa B.R., and Rice K.C. Cannabinoid receptor localization in brain. Proceedings of the National Academy of Sciences of the United States of America 87 (1990) 1932-1936
12. 1 receptor-mediated inhibition of NMDA- and kainate-stimulated noradrenaline and dopamine release in brain. Naunyn-Schmiedeberg's Archives of Pharmacology 359 6 (1999) 466-470
13. 1 cannabinoid receptor antagonists. Journal of Medicinal Chemistry 48 6 (2005) 1823-1838
14. 1 antagonist, blocks nicotine-conditioned place preferences. Neuroreport 15 13 (2004) 2139-2143
15. 1 receptor antagonists as promising new medications for drug dependence. Journal of Pharmacology and Experimental Therapeutics 312 3 (2005) 875-883
16. Lesscher H.M., Hoogveld E., Burbach J.P., van Ree J.M., and Gerrits M.A. Endogenous cannabinoids are not involved in cocaine reinforcement and development of cocaine-induced behavioural sensitization. European Neuropsychopharmacology 15 1 (2005) 31-37
17. Lupica C.R., and Riegel A.C. Endocannabinoid release from midbrain dopamine neurons: a potential substrate for cannabinoid receptor antagonist treatment of addiction. Neuropharmacology 48 8 (2005) 1105-1116
18. Lupica C.R., Riegel A.C., and Hoffman A.F. Marijuana and cannabinoid regulation of brain reward circuits. British Journal of Pharmacology 143 2 (2004) 227-234
19. Martin R.S., Secchi R.L., Sung E., Lemaire M., Bonhaus D.W., Hedley L.R., and Lowe D.A. Effects of cannabinoid receptor ligands on psychosis-relevant behavior models in the rat. Psychopharmacology (Berl) 165 2 (2003) 128-135
20. 3H]dopamine release and methamphetamine-induced hyperactivity in rats. Pharmacology, Biochemistry and Behavior 80 4 (2005) 557-566
21. Munro S., Thomas K.L., and Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 365 6441 (1993) 61-65
22. Palmer S.L., Thakur G.A., and Makriyannis A. Cannabinergic ligands. Chemistry and Physics of Lipids 121 1-2 (2002) 3-19
23. Pertwee R.G. Pharmacology of cannabinoid receptor ligands. Current Medicinal Chemistry 6 8 (1999) 635-664
24. Pierce R.C., and Kumaresan V. The mesolimbic dopamine system: the final common pathway for the reinforcing effect of drugs of abuse?. Neuroscience and Biobehavioral Reviews 30 (2006) 215-238
25. 3 receptor function. European Journal of Pharmacology 517 1-2 (2005) 68-73
26. 3H]dopamine release. Life Sciences 80 (2007) 337-344
27. Rothman R.B., Baumann M.H., Dersch C.M., Romero D.V., Rice K.C., Carroll F.I., and Partilla J.S. Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 39 1 (2001) 32-41
28. 1 receptor-mediated modulation of evoked dopamine release and of adenylyl cyclase activity in the human neocortex. British Journal of Pharmacology 141 7 (2004) 1193-1203
29. Sulzer D., Sonders M.S., Poulsen N.W., and Galli A. Mechanism of neurotransmitter release by amphetamines: a review. Progress in Neurobiology 75 (2005) 406-433
30. Szabo B., Muller T., and Koch H. Effects of cannabinoids on dopamine release in the corpus striatum and the nucleus accumbens in vitro. Journal of Neurochemistry 73 3 (1999) 1084-1089
31. 1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions. British Journal of Pharmacology 138 4 (2003) 544-553
32. Westerink B.H., and Kikkert R.J. Effect of various centrally acting drugs on the efflux of dopamine metabolites from the rat brain. Journal of Neurochemistry 46 4 (1986) 1145-1152
33. 1 receptor antagonist AM251 inhibits cocaine-primed relapse in rats: role of glutamate in the nucleus accumbens. Journal of Neuroscience 26 33 (2006) 8531-8536
34. Zaniewska M., McCreary A.C., Przegalinski E., and Filip M. Evaluation of the role of nicotinic acetylcholine receptor subtypes and cannabinoid system in the discriminative stimulus effects of nicotine in rats. European Journal of Pharmacology 540 1-3 (2006) 96-106